{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:39:14Z","timestamp":1780508354668,"version":"3.54.1"},"reference-count":8,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open\u2010label setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Thirty patients with refractory PME (aged \u2265 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (\u2264 6 mg\/kg\/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24\u2010hour period or in 10\u2010minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a \u2265 50% decrease in myoclonic seizure frequency from baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Treatment\u2010related AEs, experienced by 53% (n = 16\/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10\/28) had a \u2265 50% reduction in myoclonic seizure frequency.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open\u2010label character of this study, further research is required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1684\/epd.2008.0168","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:49:54Z","timestamp":1711550994000},"page":"31-34","source":"Crossref","is-referenced-by-count":32,"title":["Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open\u2010label study"],"prefix":"10.1002","volume":"10","author":[{"given":"David G.","family":"Vossler","sequence":"first","affiliation":[{"name":"Epilepsy Center Washington Neuroscience Institute Renton Washington and Department of Neurology University of Washington Seattle Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan A.","family":"Conry","sequence":"additional","affiliation":[{"name":"Department of Neurology George Washington Children's National Medical Center Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome V.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Neurology Children's Mercy Hospital Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738020170011201"},{"key":"e_1_2_7_3_1","unstructured":"Eisai Ltd. Zonegran Summary of Product Characteristics (last updated 14 May 2007).Electronic Medicines Compendium(available athttp:\/\/emc.medicines.org.uk\/)."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00215.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.6.928"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000058755.38892.80"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00069-7"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.44.s11.4.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.11.021"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1684\/epd.2008.0168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T16:47:09Z","timestamp":1711558029000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1684\/epd.2008.0168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1684\/epd.2008.0168"],"URL":"https:\/\/doi.org\/10.1684\/epd.2008.0168","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}